How Will the Biosimilar Market Change in 2018?



 
“Right now, I think we’re at 7 that have been approved by the FDA, with a couple more in the pipeline. I think, as of 2015, I believe IMS Health came out with something where there were 41 of these in development. So I know that there’s probably more coming on, and I think more will come on once we get some clarity from the FDA about what direction they’re going to do as far as regulating biosimilars, but I don’t think this a trend that’s going away anytime soon. At the end, we all want to lower prices, patients need to be taken care of by specialty pharmacies, and they realize that, and I know patients have become a lot more savvy about what’s out there. So, I think everybody’s really just trying to figure out how are biosimilars going to effect the market, and how much are they going to lower the price?”

 

Related Articles

A Bluetooth-enabled, nanochannel drug delivery system administers controlled doses based on patients’ therapeutic needs.
Study finds elevated risk factors for cardiovascular disease in postmenopausal women with a history of breast cancer.
In an interview with Specialty Pharmacy Times, former NFL placekicker, Rolf Benirschke, CEO of Legacy Health Strategies, discusses how specialty pharmacists can best support patients who are undergoing treatment for IBD or Crohn Disease.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$